

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



### **DELAY IN DESPATCH OF CIRCULAR**

Reference is made to the announcement (the “**Announcement**”) of Tianda Pharmaceuticals Limited (the “**Company**”) dated 20 September 2023 in relation to, among other things, the revision of annual cap for existing continuing connected transaction with SPH and the renewal of framework agreement with SPH. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among other things, (i) further details of the 2023 Supplemental Agreement, the 2023 Framework Agreement and the respective transactions contemplated thereunder, (ii) the letter of recommendation from the Independent Board Committee regarding the 2023 Supplemental Agreement, the 2023 Framework Agreement and the respective transactions contemplated thereunder; (iii) the letter of advice from Rainbow Capital to the Independent Board Committee and the Independent Shareholders regarding the 2023 Supplemental Agreement, the 2023 Framework Agreement and the respective transactions contemplated thereunder; and (iv) a notice of the EGM will be despatched to the Shareholders in compliance with the Listing Rules on or before 12 October 2023.

As additional time is required for the Company to finalise certain information in the Circular, it is expected that the date of despatch of the Circular will be postponed from 12 October 2023 to a day falling on or before 19 October 2023.

For and on behalf of the Board  
**Tianda Pharmaceuticals Limited**  
**FANG Wen Quan**  
*Chairman and Managing Director*

Hong Kong, 12 October 2023

*As at the date of this announcement, the executive Directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the non-executive Directors are Mr. ZHONG Tao and Mr. FENG Quanming; and the independent non-executive Directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Dr. XIAN Yanfang.*